Clinical Trial

Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe

Study acronym: HP-MICI
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Clinical and experimental data suggest that dysbiosis may play a pivotal role in the pathogenesis of intestinal bowel disease (IBD). However, to the best of our knowledge, the composition of gastric and of intestinal microbiome has never been investigated in a population with IBD according to the presence/absence of Helicobacter pylori (H. pylori) in the stomach.
Trial Details
NCT Number NCT07292454
Lead Sponsor Centre Hospitalier Universitaire de la Guadeloupe
Conditions HELICOBACTER PYLORI INFECTIONS, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Enrollment 100 participants
Start Date 2025-12-15
Primary Completion 2026-12-15 (estimated)
Study Completion 2026-12-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-18